WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index
VAS = Visual Analogue Score
* Percent change from baseline.
REFERENCES
1. Bhatia et al. 2023. “Two-Year Outcomes Comparing Embosphere® Microspheres versus Imipenem Cilastatin for Genicular Artery Embolization in Patients with Moderate to Severe Knee Osteoarthritis.” Knee 41 (March): 38 ̶ 47. doi: 10.1016/j.knee.2022.12.008.
2. Little et al. 2024. “Genicular Artery Embolisation in Patients with Osteoarthritis of the Knee (GENESIS) Using Permanent Microspheres: Long-Term Results.” Cardiovasc Intervent Radiol 47, no. 12 (Dec): 1750–62. doi: 10.1007/s00270-024-03752-7.
3. Data on file
INDICATIONS FOR USE Embosphere Microspheres are indicated for arterial embolisation in patients undergoing treatment for hypervascular processes, including genicular artery embolisation (GAE) in patients with mild-to-moderate knee osteoarthritis who are refractory to standard-of-care first-line conservative treatment (e.g., physical therapy, medical therapy [NSAIDs, opioids], intra-articular corticosteroid injections).
†Embosphere used in GAE for knee osteoarthritis is CE-marked under the EU Medical Device Regulation (MDR 2017/745).
Before using any of the products mentioned, refer to Instructions for Use for indications, contraindications, warnings, precautions, and directions for use.
